2020
DOI: 10.1016/j.jid.2019.07.693
|View full text |Cite
|
Sign up to set email alerts
|

Frequent and Persistent PLCG1 Mutations in Sézary Cells Directly Enhance PLCγ1 Activity and Stimulate NFκB, AP-1, and NFAT Signaling

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

1
26
0

Year Published

2020
2020
2024
2024

Publication Types

Select...
6
2
1

Relationship

2
7

Authors

Journals

citations
Cited by 28 publications
(27 citation statements)
references
References 57 publications
1
26
0
Order By: Relevance
“…The major, comprehensive discoveries are described in a number of publications [215][216][217][218][219][220][221][222][223][224]. Interestingly, in a number of cases where functional characterization of the effect of genetic changes on PLC activity has been performed, these alterations (predominantly single aminoacid substitutions) result in an increase of PLC activity under basal and/or stimulated conditions [83,84,215,217,219,[225][226][227][228]. Consequently, terms "gain-of-function mutation" (a mutation that confers new or enhanced activity on a protein) and "hypermorphic mutation" (mutation in which the altered gene product possesses an increased level of activity) have been used when describing these PLC variants.…”
Section: Plcβ4mentioning
confidence: 99%
See 1 more Smart Citation
“…The major, comprehensive discoveries are described in a number of publications [215][216][217][218][219][220][221][222][223][224]. Interestingly, in a number of cases where functional characterization of the effect of genetic changes on PLC activity has been performed, these alterations (predominantly single aminoacid substitutions) result in an increase of PLC activity under basal and/or stimulated conditions [83,84,215,217,219,[225][226][227][228]. Consequently, terms "gain-of-function mutation" (a mutation that confers new or enhanced activity on a protein) and "hypermorphic mutation" (mutation in which the altered gene product possesses an increased level of activity) have been used when describing these PLC variants.…”
Section: Plcβ4mentioning
confidence: 99%
“…Subsequently, PLCG1 mutations were discovered in another type of rare malignancies, T-cell lymphomas, including cutaneous T-cell lymphoma (CTCL) and adult T-cell leukaemia/lymphoma (ATLL or ATL; linked to a human T-lymphotropic virus type 1/HTLV-1) [222,228,[243][244][245][246][247][248][249][250][251][252][253][254][255][256][257][258][259][260]. In ATL, PLCG1 is the most frequently mutated gene (36%, based on the largest study [222]) and, as in other T-cell lymphomas, have been linked to the aberrant TCR signal transduction pathway.…”
Section: J O U R N a L P R E -P R O O Fmentioning
confidence: 99%
“…It was shown previously that mutated PLCG1 increases the survival signaling via NF-kB, NFAT and AP-1. 11,44 Mutated STAT3 was also shown to have a pathogenic role in CTCL. 45,46 .…”
Section: Discussionmentioning
confidence: 99%
“…In the present study, curcumin downregulated ALK, as well as the phosphorylated form of one of the downstream effectors of ALK, PLCγ, which may serve an important role in the progression of the disease. Bona fide gain of function mutations of PLCγ1, the PLCγ form predominantly expressed by T cells ( 86 ), lead to the constitutive activation of proximal and distal PLCγ1 signaling cascades, including the activation of NF-κB, with the inhibition of this pathway resulting in decreased CTCL cell proliferation and viability ( 87 89 ).…”
Section: Discussionmentioning
confidence: 99%